Electromed, Inc. (ELMD)

US — Healthcare Sector
Peers: NPCE  KIDS  SRDX  FNA  OSA  LIVN  LUNG  IRMD  OFIX  ITGR  AORT  AXGN  CNMD  SGHT 

Automate Your Wheel Strategy on ELMD

With Tiblio's Option Bot, you can configure your own wheel strategy including ELMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ELMD
  • Rev/Share 7.2324
  • Book/Share 5.1725
  • PB 3.9459
  • Debt/Equity 0.0
  • CurrentRatio 5.1927
  • ROIC 0.1519

 

  • MktCap 171160709.0
  • FreeCF/Share 1.4031
  • PFCF 14.3603
  • PE 24.2121
  • Debt/Assets 0.0
  • DivYield 0
  • ROE 0.165

 

  • Rating B+
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 2
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation ELMD B. Riley Securities -- Buy -- $38 Feb. 20, 2025

News

Here is Why Growth Investors Should Buy Electromed (ELMD) Now
ELMD
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive

Electromed (ELMD) could produce exceptional returns because of its solid growth attributes.

Read More
image for news Here is Why Growth Investors Should Buy Electromed (ELMD) Now
Electromed, Inc. Schedules its Third Quarter Fiscal 2025 Financial Results Conference Call for May 13, 2025 at 5:00 p.m. ET
ELMD
Published: April 29, 2025 by: Business Wire
Sentiment: Neutral

NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its financial results press release for the fiscal 2025 third quarter ended March 31, 2025, on May 13, 2025 after the close of the stock market. Company management will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Interested parties may participate in the call.

Read More
image for news Electromed, Inc. Schedules its Third Quarter Fiscal 2025 Financial Results Conference Call for May 13, 2025 at 5:00 p.m. ET
Electromed, Inc. (ELMD) Q2 2025 Earnings Call Transcript
ELMD
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Neutral

Electromed, Inc. (NYSE:ELMD ) Q2 2025 Earnings Conference Call February 11, 2025 5:00 PM ET Company Participants Mike Cavanaugh - IR, Westwicke Partners James Cunniff - President, CEO & Director Bradley Nagel - CFO, Treasurer & Company Secretary Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Operator Good afternoon, and welcome to the Electromed Second Quarter 2025 Earnings Conference Call. All participants will be in listen-only mode.

Read More
image for news Electromed, Inc. (ELMD) Q2 2025 Earnings Call Transcript

About Electromed, Inc. (ELMD)

  • IPO Date 2010-08-13
  • Website https://smartvest.com
  • Industry Medical - Devices
  • CEO Mr. James L. Cunniff
  • Employees 174

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system; SmartVest SQL System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment; and SmartVest Connect, a wireless technology with personalized HFCWO therapy management portal for patients with compromised pulmonary function. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products primarily to home health care market for patients with bronchiectasis, cystic fibrosis, and neuromuscular disease. Electromed, Inc. markets its products primarily to physicians and health care providers, as well as directly to patients. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota.